P-6. Outcomes of Early Oral Antibiotic Treatment for Uncomplicated Enterococcal Bacteremia

Abstract Background Enterococcus spp. is a common cause of healthcare-associated bloodstream infections. Limited data exists on the efficacy and safety of oral antibiotic therapy for enterococcal bacteremia. This study compares the clinical outcomes of adults with uncomplicated enterococcal bacteremia treated with intravenous (IV) therapy versus an early transition to oral (PO) therapy. Methods Retrospective cohort study of adult patients with Enterococcus spp. bacteremia between January 1, 2021 and August 1, 2024 at two tertiary medical centers. Patients hospitalized with uncomplicated enterococcal bacteremia with appropriate source control were included. Notable exclusion criteria include polymicrobial bacteremia, positive blood cultures for ≥ 48 hours, and evidence of invasive infection. The primary outcome was clinical cure at 90 days. Secondary outcomes included infection recurrence, hospital length of stay (LOS), treatment duration, and 90-day mortality. Safety outcomes, dosing strategies, and treatment durations were also evaluated. Results 73 patients were included. 35 patients were transitioned to PO therapy with linezolid (21/35, 60%) and amoxicillin (11/35, 31%) most commonly. Infection sources were predominantly intra-abdominal (41%) and genitourinary (35%). 26 (36%) patients were considered immunocompromised. Clinical cure rates were similar between the IV to PO vs. the IV group (88.6% vs. 81.6%; p=0.4). Infection recurrence was low between the two groups (5.3% vs. 7.9%; p = 1.0). The median antibiotic duration was comparable between the IV to PO vs. the IV group (14 days vs. 15 days; p=0.4). The median time to transition to PO therapy was 6 days [IQR, 3.5-8.5]. Hospital length of stay was significantly shorter in the IV to PO group compared to the IV group (9 days vs. 17 days; p=0.019). No significant difference was observed in 90-day mortality. Antibiotic-associated adverse effects were similar between groups. Conclusion Clinical cure rates were comparable between the IV to PO and IV only group, and transitioning to PO antibiotics was associated with a shorter hospital LOS. These findings suggest that early transition to PO antibiotics may be a viable strategy for managing uncomplicated enterococcal bacteremia. Disclosures All Authors: No reported disclosures

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.237
Primary Topic
Antimicrobial Resistance in Staphylococcus
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-6. Outcomes of Early Oral Antibiotic Treatment for Uncomplicated Enterococcal Bacteremia

Alyssa R. Letourneau, M. Schultze, Alexander E Rock, Tiffany Wu et al.
Open Forum Infectious Diseases
Antimicrobial Resistance in Staphylococcus
article

P-6. Outcomes of Early Oral Antibiotic Treatment for Uncomplicated Enterococcal Bacteremia

Alyssa R. Letourneau, M. Schultze, Alexander E Rock, Tiffany Wu, Eric M Gillett, Cecilia Li
article en

Abstract

Abstract Background Enterococcus spp. is a common cause of healthcare-associated bloodstream infections. Limited data exists on the efficacy and safety of oral antibiotic therapy for enterococcal bacteremia. This study compares the clinical outcomes of adults with uncomplicated enterococcal bacteremia treated with intravenous (IV) therapy versus an early transition to oral (PO) therapy. Methods Retrospective cohort study of adult patients with Enterococcus spp. bacteremia between January 1, 2021 and August 1, 2024 at two tertiary medical centers. Patients hospitalized with uncomplicated enterococcal bacteremia with appropriate source control were included. Notable exclusion criteria include polymicrobial bacteremia, positive blood cultures for ≥ 48 hours, and evidence of invasive infection. The primary outcome was clinical cure at 90 days. Secondary outcomes included infection recurrence, hospital length of stay (LOS), treatment duration, and 90-day mortality. Safety outcomes, dosing strategies, and treatment durations were also evaluated. Results 73 patients were included. 35 patients were transitioned to PO therapy with linezolid (21/35, 60%) and amoxicillin (11/35, 31%) most commonly. Infection sources were predominantly intra-abdominal (41%) and genitourinary (35%). 26 (36%) patients were considered immunocompromised. Clinical cure rates were similar between the IV to PO vs. the IV group (88.6% vs. 81.6%; p=0.4). Infection recurrence was low between the two groups (5.3% vs. 7.9%; p = 1.0). The median antibiotic duration was comparable between the IV to PO vs. the IV group (14 days vs. 15 days; p=0.4). The median time to transition to PO therapy was 6 days [IQR, 3.5-8.5]. Hospital length of stay was significantly shorter in the IV to PO group compared to the IV group (9 days vs. 17 days; p=0.019). No significant difference was observed in 90-day mortality. Antibiotic-associated adverse effects were similar between groups. Conclusion Clinical cure rates were comparable between the IV to PO and IV only group, and transitioning to PO antibiotics was associated with a shorter hospital LOS. These findings suggest that early transition to PO antibiotics may be a viable strategy for managing uncomplicated enterococcal bacteremia. Disclosures All Authors: No reported disclosures

Open Forum Infectious DiseasesVol. 13(Supplement_1)
Brigham and Women's Hospital (US), Massachusetts General Hospital (US)
Good health and well-being
Openalex Percentile: Top 91%
Antimicrobial Resistance in Staphylococcus
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.